New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
06:07 EDTAGN, VRXValeant raises proposal for Allergan by $10.00 per share to $58.30 per share
Valeant Pharmaceuticals (VRX) announced that it has submitted an increase to its April 22 proposal to merge with Allergan (AGN) to Allergan's board. In a letter to Allergan's board, Valeant stated, "Our revised offer is based on specific feedback we received in our discussions and offers Allergan shareholders, for each Allergan share $58.30 in cash, representing an increase of $10, or approximately 21%, in the cash portion of the consideration, 0.83 of a Valeant share and a new CVR related to DARPin sales which would provide up to approximately $25.00 per share of additional value based on the approximately $20B in potential cumulative 10-year DARPin sales referred to in your May 12th presentation. We are prepared to fund up to $400M to develop DARPin and will pay 40% of the net sales of DARPin referred to in your May 12 presentation after recovery of our shareholders' investment in DARPin development expenses. Shareholders will continue to be able to elect their mix of cash and shares, subject to proration, as well as receiving the CVR. We would propose to retain Allergan employees to continue development of DARPin and will ask Allergan to provide us a list of eight independent scientific and business leaders. From these eight, we will select five to oversee DARPin development and decide on all go / no-go decisions as the compound progresses."
News For VRX;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTVRX, AGNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 13, 2015
14:00 EDTAGNActavis says Allergan deal could close as early as Q1, as late as Q2
Subscribe for More Information
12:49 EDTVRXValeant CEO says 'unlikely' to work with Bill Ackman again
Subscribe for More Information
12:48 EDTVRXValeant CEO says will have a 'number of clean quarters in a row'
Valeant CEO Michael Pearson said on CNBC that his company will have a "number of clean quarters in a row" in an effort to dispute attacks on its business model.
10:56 EDTVRXValeant sees continuation of Q3 trends in Q4
Subscribe for More Information
10:46 EDTVRXValeant doesn't see need to 'push a large deal for sake of doing large deal'
Sees double digit organic growth in 2014, 2015 and beyond. Says business development a priority for cash flow. Sees pursuing small and medium sized deals. Says doesn't see a need to "push a large deal for the sake of doing a large deal." Comments made at the JP Morgan Healthcare Conference. Valeant shares are up 2.1% to $158.76 in morning trading.
10:39 EDTVRXValeant repeats FY15 EPS view $10.10-$10.40, revenue $9.2B-$9.3B
Subscribe for More Information
10:38 EDTVRXValeant repeats Q4 cash EPS view $2.55+ vs. previous view $2.45-$2.55
Repeats Q4 revenue view $2.1B-$2.3B. Sees Q4 adjusted cash flow from operations about $600M. Says absorbed additional negative Fx impact of ~$40M to revenue, ~10c to cash EPS. Says FDA submission for Vesneo on track for Q2. Sees submission for sub-micron loteprednol gel 0.38% in late Q3, early Q4, and expects to launch product in 3Q16. Sees filing NDA for Arestin LCM in 2H15. Sees >12% same store organic growth for total company in Q4, >10% for FY. Sees Bausch + Lomb organic growth >10% for FY. Sees continued strong performance from Jublia, other recent product launches. Strategic initiates for 2015 include 10%-12% organic growth, cash conversion rate of >90%, achieve $500M+ revenues for key launch programs, including Jublia, Ultra, Luzu, Retin-A Micro 0.08%, Onexton. Comments from slides being presented at the JP Morgan Healthcare Conference.
07:42 EDTVRXJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
07:39 EDTVRX, AGNAmerican Academy of Cosmetic Surgery to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use